Substituted isoquinolines as ultra short acting neuromuscular blockers
Patent Information
- Application Number
- MYPI1998001252
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 1997-11-27
- Filing Date
- 1998-03-23
- Publication Date
- 1998-09-25
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current neuromuscular blocking agents lack an ultra-short duration option, leading to safety concerns and side effects, particularly with depolarizing agents, and non-depolarizing agents have limitations such as histamine release and prolonged action.
Development of novel substituted isoquinoline compounds with a butanedioate or butenedioate linker, providing potent non-depolarizing neuromuscular blockade of ultra-short duration (about 5 to 15 minutes) with rapid onset and reduced histamine release, suitable for emergency and surgical use.
The compounds offer increased safety and reduced side effects compared to existing agents, maintaining ultra-short duration and rapid recovery with administration by bolus or infusion, and are reversible with known agents like neostigmine, addressing the need for a safer, more effective neuromuscular blocker.
Abstract
Description
SUBSTITUTED ISOQUINOLINES AS ULTRA SHORT ACTINGNEUROMUSCULAR BLOCKERS.The present invention relates to novel compounds, methods for the preparationof such compounds, pharmaceutical compositions containing them and their use asneuromuscular blocking agents of ultra-short duration.In anesthesia, neuromuscular blocking agents are used to provide skeletalmuscle relaxation during surgery and during intubation of the trachea. Neuromuscularblockers are generally classified by both the mechanism of action (depolarizing or non-depolarizing) and the duration of action (ultrashort, short, intermediate, and long). See,Bedford, R., "From the FDA", Anesthesiology, 82(1), 33a, 1995. Non-depolarizingneuromuscular blocking agents include long-duration agents such as d-tubocurarine,pancuronium, gallamine, diallyltoxiferine and toxiferine, intermediate-duration agentssuch as atracurium and vecuronium, and short-duration agents such as mivacurium. Seee.g., U.S. 4,179,507, U.S. 4,701,460, U.S. 4,761,418 and U.S. 5,454,510. Conventionalnon-depolarizing agents typically exhibit a 20 to 180 minute duration of action whenused as skeletal muscle relaxants. Presently there are no ultrashort duration, non-depolarizing neuromuscular blocking agents in clinical use.Depolarizing agents include succinylcholine and decamethonium. Due to theirdepolarizing mechanism of action, these agents can have severe side effects such ascardiac arrest and death, hyperkalemia, malignant hyperthermia, severe muscle pain,cardiac arrhythmias, increased intraocular pressure and increased intragastric tension.Conventional depolarizing agents exhibit shorter durations of action, e.g., 10 to 15minutes in humans. Succinylcholine has a rapid onset and ultrashort duration of actionand is the only ultra-short acting neuromuscular blocker in clinical use. Despite itsundesirable side effect profile, no other ultrashort acting agent is available and thus it iscurrently the preferred agent for emergency use. The ultra-short duration of action isextremely important in emergency situations. Use of longer duration agents could leadto serious brain damage and death.Non-depolarizing agents are generally believed to be safer and more clinicallydesirable than depolarizing agents, and clinicians have long recognized the need for anon-depolarizing neuromuscular blocker that has an ultra-short duration of action. See,Miller, R.D. Anesthesia and Analgesia 61(9), 721, 1982; and Belmont, M.R., CurrentOpinion in Anaesthesiology, 8, 362, 1995. However, non-depolarizing agents canexhibit side effects not specifically related to their mechanism or duration of action.For example, the long-duration agents pancuronium and gallamine have effects on theautonomic nervous system and may cause an increase in heart rate (tachycardia).Intermediate- and short-duration agents such as atracurium besylate and mivacuriumchloride may also exhibit the side effect of histamine release. Histamine release hasundesirable effects on blood pressure and heart rate, and some physicians believe thatrelease of large amounts of histamine can cause life-threatening anaphylaxis in somepatients.It has now been discovered that compounds of Formula (I) include potent non-depolarizing neuromuscular blocking agents of ultra-short duration, e.g., about 5 to 15minutes, that will provide both increased safety over known depolarizing ultrashortacting agents, e.g. succinylcholine, and a reduced capacity to release histamine overother non-depolarizing agents such as atracurium and mivacurium. In addition, theyhave a rapid onset of action and are reversed by treatment with known reversal agentssuch as neostigmine, both very important features in emergency situations and in otherprocedures. These agents maintain their ultrashort duration of action and rapidspontaneous recovery when administered by either bolus or continuous infusion and arewithout the cumulative effects observed with other neuromuscular blockers(pancuronium, vecuronium). Thus, compounds of the present invention should providea significant advantage in the emergency, routine surgical, and post-operative settings.Accordingly, the present invention provides compounds of Formula (I):wherein X is halogen; h is from 1 to 2; Y is hydrogen or methoxy; Z and Z aremethyl; W1 and W are carbon; and A is a pharmaceutical^ acceptable anion.The compounds of Formula (I) contain two substituted isoquinolinium moietiesconnected by an aliphatic linker. The two substituted isoquinolinium moieties can beconveniently distinguished by referring to them as the "left head" and the "right head",where the left head contains W and the right head contains W . The aliphatic linker isthe portion of the compound of Formula (I) denoted by the following Formula (i).The solid and dashed lines (......)indicates a double or single bond.A suitable class of compounds of Formula (I) is that wherein X is chlorine orfluorine. Particularly preferred halogen substitutions are monochloro, monofluoro anddifluoro.The aliphatic linker portion of compounds of Formula (I), as described byFormula (i), comprises a butanedioate or butenedioate moiety. Suitably, compounds ofFormula (I) wherein the aliphatic linker comprises a butenedioate moiety may exist ineither the E or Z configuration or as mixtures of E and Z isomers. Preferably thebutenedioate moiety of compounds of Formula (I) is a fumarate.The term fumarate as used herein refers to a butenedioate moiety wherein thetwo ester carbonyl groups are oriented trans to one another.A preferred class of compounds of Formula (I) is that wherein the aliphaticlinker is a butanedioate moiety and X represents chlorine or fluorine and h is 1 or 2. Aparticularly preferred class of compounds of Formula (I) is that wherein the aliphaticlinker is a butanedioate moiety and X represents fluorine and h is 1 or 2. Compoundsof Formula (I) wherein the aliphatic linker is a butanedioate moiety, X representsfluorine and h is 2 are most preferred.Another preferred class of compounds of Formula (I) is that wherein thealiphatic linker is a butenedioate moiety and X represents chlorine or fluorine. Aparticularly preferred class of compounds of Formula (I) includes those wherein thealiphatic linker is a butenedioate moiety, X represents chlorine or fluorine, h is 1 andthe butenedioate moiety is a fumarate. Compounds of Formula (I) wherein the aliphaticlinker is a butenedioate moiety, X represents chlorine, h is 1 and the butenedioatemoiety is a fumarate are most preferred.The compounds of Formula (I) contain four chiral centres. The carbon atoms(denoted as W and W ) and each quaternary nitrogen atom in the isoquinoliniummoieties are chiral. Each of the four chiral centres may independently exist in either theR or S configuration. Accordingly, it would be apparent to those skilled in the art thateach compound within Formula (I) may exist in sixteen distinct optical isomeric forms.The scope of the present invention extends to cover each and every isomer of thecompounds of Formula (I) either individually or in admixture with other isomers, andall mixtures of such isomers. Suitably W1 is in the R configuration, the N attached toZ is in the S configuration, W is in either the R or S configuration, and the N attachedto Z is in either the R or S configuration. Preferably W is in the R configuration, theN attached to Z is in the S configuration, W is in the S configuration, and the Nattached to Z is in either the R or S configuration. Compounds of Formula (I) whereinW1 is in the R configuration, W2 is in the S configuration, the N attached to Z1 is in theconfiguration and the N attached to Z is in the R configuration are most preferred.Particularly preferred compounds of Formula (I) include:(Z)-2-Chloro-4-{3-[( 1S, 2tf)-6,7-dimethoxy-2-methyl-1 -(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydro-2-isoquinolinio]propyl } -1 - {3- {(1 / ?, 25)-6,7-dimethoxy-2-methyl-1 -[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-2-isoquinolinio} propyl} -2-butenedioate dichloride,2,2-Difluoro-4-{3-[(lS', 2 / ?)-6,7-dimethoxy-2-methyl-1 -(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydro-2-isoquinolinio]propyl} 1 - { 3 - {(1 if, 2S)-6,7-dimethoxy-2-methyl-1 -[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-butanedioate dichloride,(Z)-4-{3-[(15,2i?)-6,7-Dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl} -1 - {3 - {(1 / ?,25)-6,7-dimethoxy-2-methyl-1 -[(3,4,5 -trimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-2-isoquinolinio }propy 1} -2-fluoro-2-butenedioate dichloride and2,2-Difluoro-4-{3-[(l S, 2J?j-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydro-2-isoquinolinio]propyl }-l-{3-{(l / ?, 2S)-2-methyI-6,7,8-trimethoxy-1 -[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}butanedioate dichloride.Since the pharmacological activity of the compounds of the invention resides inthe cation, the nature of the anion A" is relatively unimportant. However, fortherapeutic purposes it is, preferably, pharmaceutically acceptable to the recipient of thecompounds. Examples of pharmaceutically acceptable anions include iodide, mesylate,tosylate, bromide, chloride, hydrogen sulphate, sulphate / 2, phosphate / 3, hydrogenphosphate / 2, acetate, besylate, succinate / 2, maleate, naphthalenesulphonate andpropionate. Both pharmaceutically acceptable salts and salts which are not thusacceptable may be useful for isolating and / or purifying the compounds of the invention.The unacceptable salts may also be useful in that they may be converted into acceptablesalts by techniques well known in the art.The compounds of Formula (I) are used as neuromuscular blocking agentsduring surgery, for intubation of the trachea or during electroshock therapy. They maybe administered parenterally, e.g., by intramuscular or intravenous injection of asolution. Accordingly, the present invention also provides a method for producingmuscle relaxation in a mammal, which comprises administering to the mammal aneffective neuromuscular blocking amount of a compound of Formula (I). The dosagefor each subject may vary, however, a suitable intravenous amount or dosage of thecompounds of Formula (I) to obtain paralysis in mammals would be 0.01 to 5.0 mg / kgof body weight, and most preferably, 0.02 to 0.5 mg / kg of body weight, the above beingbased on the weight of the di-cation which is the active ingredient. The dosage forintramuscular administration is two to eight times the intravenous dose.In a further aspect, the present invention provides compounds of Formula (I) foruse in therapy, for example to induce neuromuscular blockade in surgery or forintubation of the trachea. The present invention also provides the use of a compound ofFormula (I) in the manufacture of a medicament for inducing neuromuscular blockadein a mammal, including in a human.While it is possible for the compounds of Formula (I) to be administered as thebulk active chemicals, it is preferred to present them in the form of a pharmaceuticalformulation for parenteral administration. Accordingly, the present invention providesa pharmaceutical formulation which comprises a compound of Formula (I), ashereinbefore defined and a pharmaceutically acceptable carrier.Where the pharmaceutical formulation is for parenteral administration, theformulation may be an aqueous or non-aqueous solution or mixture of liquids, whichmay contain bacteriostatic agents, antioxidants, buffers or other pharmaceuticallyacceptable additives. Alternatively the compounds may be presented as lyophilizedsolids for reconstitution with water (for injection) or dextrose or saline solutions. Suchformulations are normally presented in unit dosage forms such as ampoules ordisposable injection devices. They may also be presented in multi-dose forms such as abottle from which the appropriate dose may be withdrawn. All such formulationsshould be sterile.A suitable dose to obtain a neuromuscular block for adult humans (150 lbs. or70 kg) is 0.5 to 150 mg and more preferably 3.5 to 50 mg. The compounds of thisinvention may optionally be administered before or after (but not simultaneously with)the depolarizing agents specified above. Thus a suitable pharmaceutical parenteralpreparation for administration to humans will preferably contain 0.1 to 20 mg / ml of thecompounds of Formula (I) in solution or multiples thereof for multi-dose vials.A simple and preferred formulation is a solution of the compound of Formula (I)in water or dextrose solution. This may be prepared by dissolving the compound inpyrogen-free, sterile water or water containing dextrose, with or without a preservativeand sterilizing the solution. Alternatively, it may be prepared by dissolving the sterilecompound in pyrogen-free, sterile water or a sterile dextrose solution under asepticconditions. Particularly preferred formulations have a pH of about 2.0 to 5.0.The compounds of Formula (I) may also be administered as an infusion of adextrose solution or saline solution, e.g., Ringer's solution in drip form.The compounds may also be administered in other solvents (usually as a mixedsolvent with water) such as alcohol, polyethylene glycol and dimethylsulphoxide. Theymay also be administered intramuscularly (as a drip if required) as a suspension a orsolution.General Description of ProcessesUnless otherwise indicated, Y, Xh, and A" described in the formulae whichfollow are as defined in Formula (I) above. W corresponds to W1 and W2 of Formula12 12(I), Z corresponds to Z and Z of Formula (I) and X h and X h correspond to Xh ofFormula (I). Unless otherwise specified T represents hydroxyl or halide.Another aspect of the present invention is a process for the preparation ofcompounds of Formula (I). Compounds of Formula (I) may be prepared by reactingtwo equivalents of a compound of Formula (III):wherein Y is hydrogen or methoxy; Z is methyl; W is carbon; n is 0 or 1; and A is apharmaceutically acceptable anion;with one equivalent of a compound of Formula (VII):in an aprotic solvent. The preferred method of coupling compounds of Formula (III)with compounds of Formula (VII) involves mixing the diacid or diacid chloridederivative of (VII) (wherein T is hydroxyl or halide, e.g. CI) with two equivalents of acompound of Formula (III) in a chlorinated organic solvent at ambient or elevatedtemperatures.A further aspect of the present invention provides another process for thepreparation of compounds of Formula (I). Compounds of Formula (I) may be preparedby coupling two different compounds of Formula (III) with one equivalent of acompound of Formula (VII). Reactions of this type are preferably carried out bypreparing an equimolar solution of two different compounds of Formula (III) in achlorinated organic solvent followed by addition of one equivalent of a diacid chloridederivative of (VII) (e.g., T is CI). This technique generates a statistical mixture of 3different compounds of Formula (I) (ignoring stereochemical considerations and linkerregiochemistry) and the major component of this mixture is always the compound ofFormula (I) containing two different head groups; i.e., a mixed-head compound ofFormula (I). One or more of these compounds may be separated from the mixture bychromatographic techniques. This may be followed by the introduction ofpharmaceutically acceptable counterions (A~) by conventional ion exchange techniques.Compounds of Formula (III) wherein n is 0 are novel intermediates for the preparationof compounds of Formula (I) and represent a further aspect of the invention.Compounds of Formula (III) may be prepared by two general processes whichform a further aspect of the invention. A first process involves quaternization ofcompounds of Formula (V) (defined herein):wherein Y is hydrogen or methoxy; Z is methyl; W is carbon; and n is 0 or 1 withcompounds of Formula (VIII) (defined herein):where the substituent A in (VIII) is a suitable leaving group (e.g., wherein A is I, Br, CI,0S02Me, 0S02PhCh3) and corresponds to the anion, A"; and optionally converting theanion (A~) in the resulting compound of Formula (III) into another anion (A~) byconventional ion exchange techniques. Reactions of compounds of Formula (V) withcompounds of Formula (VIII) are preferably carried out in polar aprotic solvents atelevated temperatures in the presence of sodium carbonate. Compounds of Formula(III) prepared by this process are generated as mixtures of cis / trans stereoisomers andseparation of cis / trans isomers of (III) typically requires chromatographic techniques,wherein the terms cis and trans refer to the spatial orientation of the aryl group attachedto W relative to that of the alkanol group attached to N.A second process for the preparation of compounds of Formula (III) involvesalcoholysis or hydrolysis of zwitterionic compounds of Formula (IX) (defined herein):wherein Y is hydrogen or methoxy; Z is methyl; W is carbon; and n is 0 or 1.Alcoholysis of a compound of Formula (IX) may be performed in any suitablealcohol in the presence of a mineral acid and is preferably carried out in methanolsolutions of hydrogen chloride at ambient temperature. Compounds of Formula (IX)are prepared by the quaternization of compounds of Formula (V) with cyclic sulfates ofFormula (IV):Reactions of compounds of Formula (V) with compounds of Formula (IV) arepreferably carried out in polar aprotic solvents at elevated temperatures. Compounds ofFormula (IX) prepared by this process are generated as mixtures of cis / trans isomers;however, cis / trans mixtures of compounds of Formula (IX) may be separated byselective crystallization of the trans isomer of compounds of Formula (IX) from themixture. Selective crystallization of trans isomers of compounds of Formula (IX) arepreferably accomplished with polar aprotic solvents such as acetonitirile or acetone.This process is the preferred method of preparation of compounds of Formula (III),especially trans isomers of compounds of Formula (III) where the alkanol side chain((CH2)3OH) and the phenyl (n-0) or benzyl (n-1) substituent are oriented trans to oneanother in space, and represents a further aspect of the present invention. Compoundsof Formula (IX) are novel intermediates and represent another aspect of the invention.Another aspect of the invention comprises a novel process for the preparation ofcompounds of Formulae (I) and (II). The preparation of compounds of Formula (I)involves coupling a compound of Formula (II):wherein T is hydroxyl or halide; Y is hydrogen or methoxy; Z is methyl; W is carbon; nis 0 or 1; h is 1 or 2; and A is a pharmaceutically acceptable anion to a compound ofFormula (III).These reactions are preferably carried out by addition of a compound ofFormula (III) to the acid or acid chloride derivative of (II) (wherein T is hydroxyl orhalide, e.g. CI) in a chlorinated organic solvent at ambient or elevated temperatures.The acid chloride derivatives of compounds of Formula (II) (e.g., wherein T is CI) maybe prepared from the corresponding carboxylic acids of compounds of Formula (II)(e.g., wherein T is OH) by methods well known to those skilled in the art.Compounds of Formula (II) (e.g., wherein T is OH) are obtained by ringopening of compounds of Formula (VI) (defined herein):with compounds of Formula (III). These reactions are preferably carried out by mixingcompounds of Formulae (III) and (VI) in chlorinated organic solvents at ambient orelevated temperatures. If necessary, these reactions may be facilitated by the additionof a catalyst such as imidazole. These methods may be followed by the introduction ofpharmaceutically acceptable counterions (A-) by conventional ion exchange techniques.Ring opening of halogenated cyclic anhydrides of compounds of Formula (VI) (e.g., Xis CI or F) with compounds of Formula (III) can occur selectively to give compounds ofFormula (II) (e.g., X is CI or F; T is OH). In these reactions, the hydroxyl group of (III)reacts preferentially at the carbonyl group of compounds of Formula (VI) adjacent tothe halogen atom. This process is the preferred method for the preparation of mixed-head compounds of Formula (I). Compounds of Formula (II) are novel intermediates inthe preparation of compounds of Formula (I) and represent another aspect of theinvention.A further aspect of the present invention provides a process for the conversionof one compound of Formula (II) into another compound of Formula (II).Monohalogenated alkenedioates of Formula (lib) (e.g., Xis CI or F; his 1):may be prepared by a process which involves elimination of hydrogen halide (HX2)from vicinal dihalo alkanedioates of Formula (Ha) (e.g., X1 and X2 are independentlyCI or F; T is hydroxyl or halide; h is 1):Compounds of Formula (Ila) are prepared by the reaction of compounds ofFormula (III) with compounds of Formula (Via) (X=Br, CI, F and h is 1):These reactions are preferably carried out by mixing compounds of Formulae(III) and (Via) in chlorinated organic solvents at ambient or elevated temperatures. Ifnecessary, these reactions may be facilitated by the addition of a catalyst such asimidazole. These methods may be followed by the introduction of pharmaceutical^acceptable counterions (A-) by conventional ion exchange techniques.The transformation of compounds of Formula (Ha) into compounds of Formula(lib) is typically performed by treatment of (Ila) with an excess of a tertiary amine, suchas triethyl amine, in polar aprotic or chlorinated organic solvents at 0°C. In thiselimination process, the hydrogen atom (H) vicinal to the ester carbonyl oxygen in (Ila)(a to the ester carbonyl) is abstracted selectively. The resulting compounds of Formula(lib) may be converted to monohalogenated alkenedioates of Formula (I) by methodsdescribed herein.Another aspect the present invention provides a process for the conversion ofone compound of Formula (I) into another compound of Formula (I).Monohalogenated alkenedioates of Formula (lb):may be prepared by elimination of hydrogen halide (HX) from geminal dihaloalkanedioates of Formula (la) (e.g., X is CI or F; h is 2).Elimination of HX from compounds of Formula (la) are preferably carried outwith potassium carbonate in polar aprotic solvents, such as dimethylformamide, atambient temperature.Mixed head monohalobutenedioates of Formula (I) (e.g., X is CI or F; h is 1)exist as 1:1 mixtures of regioisomers when synthesized by said process whichcomprises reacting two equivalents of a compound of Formula (III) with one equivalentof a compound of Formula (VII). However, mixed head monohalobutenedioates ofFormula (I) (e.g., X is Br, CI, F; h is 1) exist as pure regioisomers when synthesized bysaid processes comprising conversion of compounds of Formulae (la) to (lb) orconversion of compounds of Formulae (Ha) to (lib). Thus, the latter two processes arepreferred methods for the preparation of mixed head monohalobutenedioates ofFormula (I).Alkenedioate derivatives of Formulae (I) and (II) may exist as E and Zgeometric isomers; however, monohalogenated butenedioate analogs of Formula (I)preferentially exist as halofumarates such that the two ester carbonyl groups areoriented trans to one another. Compounds of Formula (I) may also exist as mixtures ofdiastereomers and one or more diastereomers may be separated from the mixture byconventional techniques; for example, chromatographic techniques.Compounds of Formulae (IV), (V) and (VI), diacid chloride derivatives of (VII)and compounds of Formula (VIII) are commercially available or may be prepared bypublished processes for the preparation of the same or structurally analogouscompounds. Pure enantiomers of (V) are obtained by published asymmetric syntheticmethods, known classical resolution techniques, or chiral preparative HPLC.ExperimentalMelting points are uncorrected. All reagent chemicals were used withoutpurification. Analytical high performance liquid chromatography (HPLC) analyseswere performed on a 4 x 250 mm 5(0. Si60 LiChrosorb column (E. Merck, Darmstadt,Germany) at a flow rate of 1.6 mL / min. The mobile phase consisted of 0-25%methanol (MeOH) / dichloromethane (CH2C12) mixtures containing 0.25 mL ofmethanesulfonic acid / L. Medium pressure liquid chromatography (MPLC) separationswere performed on twin Porasil 15-20(0. cartridges (Waters / Millipore, Milford, MA,USA) eluting with 0-20% MeOH / CH2C12 mixtures containing 0.25 mL ofmethanesulfonic acid / L. Proton nuclear magnetic resonance ( NMR) spectra of allproducts were consistent with the proposed structures. Positive ion flow injectionelectrospray mass spectra (MS) are reported in the form m / z (doubly charged positiveion, relative intensity). Elemental analyses were performed by Atlantic Microlab,Norcross, Georgia.Chlorofumaryl chloride was prepared by a reported procedure (Akhtar, M.;Botting, P.N.; Cohen, M.A. Tetrahedron 1987, 43, 5899-5908).3,4-Dihydroisoquinoline derivatives were prepared by Bishler-Napieralskicyclization of the corresponding amides with phosphorous oxychloride (Whaley, K. W.;Govindachari Org. Reactions 1951, 6, 74-150). Racemic 1,2,3,4-tetrahydroisoquinolinederivatives were prepared by reduction of their 3,4-dihydroisoquinoline precursors withsodium borohydride / methanol. iV-Methylations of 1,2,3,4-tetrahydroisoquinolinederivatives were carried out with formaline / formic acid (Kaluszyner, A.; Galun A.B. J.Org. Chem. 1961, 26, 3536-3537).The following starting materials were prepared by chiral catalytichydrogenation of their corresponding 3,4-dihydroisoquinolines by a procedure similarto that described by Noyori et al. (Uematsu, N.; Fujii, A.; Hashiguchi, S.; Ikariya, T.;Noyori, R. J. Am. Chem. Soc. 1996,118, 4916-4917) followed by jV-methylation:(1 / ?)-6,7-Dimethoxy-2-methyl-1 -(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline;(1 S>6,7-Dimethoxy-2-methyl-1 -(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline.The following starting material was obtained by classical resolution of itscorresponding 3,4-dihydroisoquinoline derivative by a procedure similar to thatdescribed by Brossi et al. (Brossi, A.; Teitel, S. Helv. Chim. Acta 1973, 54, 1564-1571)followed by jV-methylation:(1 / ?)-6,7-Dimethoxy-2-methyl-1 -(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline; and(15)-6,7-Dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydroisoquinoline;.The following starting materials were obtained by classical resolution of theircorresponding racemic mixtures by a procedure similar to that described by Swaringenet al. (U.S. Patent 4,761,418 Aug. 2, 1988):( / ?)-(-)-5'-Methoxylaudanosine;(S)-(+)-5'-Methoxylaudanosine; and(1 / ?)-2-Methyl-6,7,8 -trimethoxy-1 -[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline.Synthetic Example 1(a) (15,2*)- and (lS,2S)-6,7-Dimethoxy-2-(3-hydroxypropyl)-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3)4-tetrahydroisoquinolinium chlorideTo a mixture of (lS)-6,7-Dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydroisoquinoline (56.0 g, 0.15 mol), sodium iodide (45.0 g, 0.30 mol), sodiumcarbonate (4.0 g, 0.038 mol), and 2-butanone (600 mL) was added 3-chloropropanol(25.0 mL, 28.3 g, 0.30 mol) and the suspension was heated to reflux for 18 hours (h)under nitrogen atmosphere. Solvent was evaporated and the residue was dissolved inH20 and washed with ethyl acetate (EtOAc). The aqueous phase was stirred withDowex 1 x 8-50 (1.0 L), filtered, and saturated with sodium chloride. The aqueousmixture was extracted with chloroform (CHC13) and the combined organic layers weredried and concentrated to provide a 3:1 mixture of the (\S,2R)- and (lS^^-titleproducts, respectively as a white solid (69.5 g, 99% yield): MS m / z 432 (M+, 9).(b) (l / ?,25)- and (l / ?,2 / ?)-6,7-Dimethoxy-2-(3-hydroxypropyl)-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydroisoquinoIiniumchloride(i?)-(-)-5'-Methoxylaudanosine (23.5 g, 61.0 mmol) was subjected to a procedure togive a 2.3:1 mixture of the (\R,2S)- and (li?,22?)-title products, respectively as a yellow,hygroscopic solid (31.5 g, 100% yield). The isomers were separated by MPLC (12%MeOH / CH2Cl2, 0.25 ml methanesulfonic acid / L). The minor (\R,2R) isomer elutedfirst. The appropriate fractions were combined and most of the MeOH was removed bycoevaporation with CHCI3. The remaining CHC13 solution was washed with 1:1brine / H20, dried and concentrated to provide the (l / ?,25)-title product (10.4 g, 35%yield) and the (l / ?,2 / ?)-title product (3.7 g, 13% yield) as yellow hygroscopic solids:MS (each isomer) mfz 446 (M+, 100).(c) (Example 1.01) (Z)-2-Chloro-l-{3-[(15,2 / f)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3j4-tetrahydro-2-isoquinoIinio]propyl}-4-{3-{(l / ?,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dichloride and (Z)-2-Chloro-4-{3-[(15,2 / f)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl}-l-{3-{(l / ?,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dichloride (1:1)To a solution of the product mixture from step a (2.4 g, 5.1 mmol) and the (\R,2S)-isomer from step b (2.34 g, 4.9 mmol) in 1,2-dichloroethane (DCE) (30 mL) was addedchlorofumaryl chloride (0.83 g, 4.4 mmol) and the solution was stirred at roomtemperature (rt) for 18 h. The solvent was evaporated and the remaining residue waspurified by MPLC (5-20% MeOH / CH2Cl2, 0.25 mL methanesulfonic acid / L). Theappropriate fractions were combined and most of the MeOH was removed bycoevaporation with CHC13. The remaining CHCI3 solution was washed with 1:1brine / H20, dried and concentrated. Lyophilization provided a 1:1 mixture of the titleproducts as a white solid (0.70 g, 15% yield): MS m / z 496 (M2+, 100).The following compounds were prepared by a procedure similar to SyntheticExample 1:(Example 1.02): (Z)-2-Chloro-l-{3-[(l / ?,25)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl}-4-{3-{(l / ?,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methylj-1,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dichloride and (Z)-2-Chloro-4-{3-[(li?,25)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl}-l-{3-{(l / ?,2iS)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3j4-tetrahydro-2-isoquinolinio]propyl}-2-butenedioate dichloride (1:1)MS m / z 496 (M2+, 100).(Example 1.03): (Z)-2-Chloro-l-{3-[(15,2 / f)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxy phenyl)-1,2,3,4-tetrahydro-2-isoquinoliniol propyl}-4-{3-{(1 / f,25")-2-methy 1-6,7,8-trimethoxy-l-[(3,4,5-trimethoxyphcnvl)methyl|-1,2,3,4-tetrahv dro-2-isoquinolinio}propyl}-2-butenedioate dichloride and (Z)-2-ChIoro-4-{3-[(lS,2 / ?)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyI)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl}-l-{3-{(l / ?,25)-2-methyl-6,7,8-trimethoxy-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dichloride (1:1)MS m / z 511 (M2+, 100).(Example 1.04): (Z)-2-Chloro-l-{3-[(l / ?,25)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,23»4-tetrahydro-2-isoquinolinio]propyl}-4-{3-{(l / ?,25)-2-methyl-6,7,8-trimethoxy-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dichloride and (Z)-2-Chloro-4-{3-[(l / ?,2S)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxvphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl}-l-{3-{(l / ?,25)-2-methyl-6,7,8-trimethoxy-l-|(3,4,5-trimethoxyphenyl)methyl]-l,2,3»4-tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dichloride (1:1)MS m / z 511 (M2+, 22).Synthetic Example 2 (Method A)(a) (2R *,3R *)-2,3-Dichlorosuccinic anhydrideA solution of maleic anhydride (10.6 g, 108 mmol) and benzoyl peroxide (5 mg, 0.02mmol) in CHC13 (250 mL) was saturated with chlorine gas and the resulting brightyellow solution was stirred for 5 h at rt. Residual chlorine was removed with a streamof nitrogen and the reaction mixture was partially concentrated. Four crops of thewhite, solid title product were obtained by filtration (11.9 g, 65% yield): mp 90-92°C.(b) (Z)-2-Chloro-l-{3-{(l / ?,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methylj-l,2,3,4-tetrahydro-2-isoquinoIinio}propyl} hydrogen 2-butenedioate monochlorideA solution of the (1R, 2<S)-title product from Synthetic Example 1, step b (3.5 g, 6.10mmol) and the product from step a (1.7 g, 10.1 mmol) in DCE (38 mL) and acetonitrile(MeCN) (2 mL) was stirred at rt overnight. The mixture was concentrated and theremaining solid was triturated with EtOAc and dissolved in MeCN (25 mL). A solutionof l,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (1.68 g, 11.0 mmol) in MeCN (6 mL)was added dropwise at 0°C and the reaction mixture was stirred at ice bath temperaturefor 1 h. The solvent was evaporated and the remaining solid was dissolved in CHC13(150 mL). This solution was washed with 2:1 brine / water containing methanesulfonicacid (4 mg / mL) and with brine. The organic layer was dried and concentrated toprovide the title product as a foam (2.6 g, 69% yield): MS m / z 578 (M+, 100).(c) (Example 2.01) (Z)-2-Chloro-4-{3-[(15,2JR)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl}-l-{3-{(l / f,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dichlorideA solution of oxalyl chloride (36 mmol) in CH2C12 (18 mL) was added dropwise to astirring solution of the product from step b (2.22 g, 3.61 mmol) in DCE (25 mL). Thereaction mixture was stirred 1 h at rt and then heated at reflux for 5 min. Excess oxalylchloride was removed in vacuo and the resulting foam was dissolved in DCE (15 mL).A solution of the product mixture from Synthetic Example 1, step a (2.00 g, 3.58 mmol)in DCE (5 mL) was added and the solution was stirred overnight at rt. The solvent wasevaporated and the mixture was purifed by MPLC as described in Synthetic Example 1,step c. Lyophilization provided the title product as a white solid (731 mg, 19% yield):MS m / z 496 (M2+, 100).The following compounds were prepared by a procedure similar to Synthetic Example2:(Example 2.02): (Z)-2-Chloro-4-{3-[(15,25)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl}-l-{3-{(l / f,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyI)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dichlorideMS m / z 496 (M2+, 100).(Example 2.03): (Z)-2-Chloro-4-{3-[(15,2 / ?)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinioJpropyI}-l-{3-{(l / ?,2.S)-2-methyl-6,7,8-trimethoxy-l-[(3,4,5-trimethoxyphenyI)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dichlorideMS / n / z511 (M2+, 100).(Example 2.04): (Z)-2-Chloro-4-{3-[(li?,25)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxy phenyl)-1,2,3,4-tetrahydro-2-isoquinolinio] propy 1}-1 - {3-{(l / ?,2.ST)-2-methyl-6,7,8-trimethoxy-l-[(3,4,5-trimethoxyphenyl)methyI]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dichlorideMS m / z 511 (M2+, 100).Synthetic Example 3 (Method B): Alternative method for thepreparation of the compound of Example 2.01(a) l,3-Dioxa-2-thiane 2,2-dioxideTo a solution of 1,3-propanediol (50.0 g, 0.65 mol) in carbon tetrachloride (CC14) (650mL) was added thionyl chloride (57.5 mL, 93.7 g, 0.79 mol) and the mixture washeated to reflux for 1.5 h. The solution was cooled to 0°C and diluted with MeCN (650mL) followed by sequential addition of ruthenium (III) chloride hydrate (81 mg, 0.39mmol), sodium periodate (210.0 g, 0.98 mol), and H20 (980 mL). The resulting orangemixture was stirred at rt for 1.5 h and then diluted with diethyl ether (Et20) (6 L). Theseparated organic phase was washed with water, saturated NaHC03 and brine. TheEt20 layer was dried and filtered through a bed of silica gel. The filtrate wasconcentrated and the resulting oil was treated with Et20 (50 mL) and hexanes (100 mL)and stored at 5°C for 18 h. Filtration of the resulting precipitate afforded the titlecompound as an off-white solid (79.0 g, 87% yield): mp 54-56°C.(b) 3-[(15,2 / ?)-6,7-Dimethoxy-2-methyI-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl-l-sulfateA mixture of (1S)-6,7-dimethoxy-2-methyl-1 -(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (36.8 g, 98.6 mmol) and the product from step a (23.7 g, 171.7mmol) in MeCN (350 mL) was heated at 65°C for 5 h. The mixture was cooled to rtand the resulting precipitate was collected by filtration and triturated with MeCN toafford the title compound as an off-white powder (30.0 g, 60% yield): mp 207-209°C;MS m / z 534 (M+23, 60), 512 (M+l, 30), 432 (M-S03, 100).(c) (15,2 / ?)-6,7-Dimethoxy-2-(3-hydroxypropyl)-2-methyI-l-(3,4,5-trimethoxyphenyl)-l,2,3»4-tetrahydroisoquinolinium chlorideAcetyl chloride (35.0 mL, 38.8 g, 0.49 mol) was added dropwise to ice-cold MeOH(350 mL) and the resulting solution was stirred for 10 minutes (min). The product fromstep b (28.1 g, 0.05 mol) was added and the reaction mixture was stirred at rt for 6 h.The solution was neutralized by careful addition of excess NaHCC>3 and the solid wasfiltered through a pad of celite. The filtrate was evaporated and the residue wasdissolved in CHC13. The resulting solid was filtered through a pad of celite and washedwith CHC13. The filtrate was evaporated, the remaining residue was dissolved in H20,and the aqueous solution was saturated with sodium chloride. The aqueous phase wasextracted with CHC13 and the organic layers were dried and concentrated to give thetitle compound as a hygroscopic white solid (25.0 g, 98% yield): MS m / z 432 (M+,100).(d) 3-{(li?,2S)-6,7-Dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3>4-tetrahydro-2-isoquinolinio}propyl-l-sulfate(1 / ?)-(-)-5 '-Methoxylaudanosine (52.6 g, 0.13 mmol) was subjected to procedure b.The resulting material was triturated with acetone to yield the title product as an off-white powder (49.3 g, 69% yield): mp 191-193°C; MS m / z 526 (M+l, 100).(e) (li?,2S)-6,7-Dimethoxy-2-(3-hydroxypropyl)-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyI]-l,2,3,4-tetrahydroisoquinolinium chlorideThe product from step d (54.5 g, 0.10 mmol) was subjected to procedure c to afford thetitle compound as a hygroscopic white foam (50.7 g, 100% yield): MS m / z 446 (M+,100).(f) (Z)-2-Chloro-l-{3-{(l / f,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio} propyl} hydrogen 2-butenedioate monochlorideA solution of the product from step e (15 g, 31.1 mmol) and the product from SyntheticExample 2, step a (6.4 g, 37 mmol) in CH2C12 (50 mL) was stirred overnight at rt. Thereaction mixture was diluted with CH2C12 (150 mL), cooled to -20°C and triethylamine(18.2 mL, 130.4 mmol) was added dropwise. The reaction was warmed to 0°C, CHC13(200 mL) was added and the mixture was washed with 2:1 brine / water containingmethanesulfonic acid (4 mg / mL). The CHCI3 layer was separated and the combinedaqueous layers were saturated with sodium chloride, acidified with concentratedhydrochloric acid (HC1) (9 mL) and back-extracted with CHC13. The combined CHC13layers were dried and concentrated and the resulting foam was triturated with Et20.The title product was collected by filtration as a tan solid (16.3 g, 86% yield): spectraldata identical to that of the title product from Synthetic Example 2, step b.(g) (Example 3.01) (Z)-2-Chloro-4-{3-[(15,2 / ?)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio| propyl}-1-{3-{(li?,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio} propyl}-2-butenedioate dichlorideThe product from step f (7.0 g, 11.4 mmol) was treated with oxalyl chloride andthen reacted with the product from step c (6.62 g, 11.9 mmol) as described in SyntheticExample 2, step c. The reaction mixture was concentrated and the resulting materialwas purified by MPLC as described in Synthetic Example 1, step c. Lyophilizationprovided the title product as a white solid (8.7 g, 72% yield): spectral data identical tothat of the title product from Synthetic Example 2, step c.Synthetic Example 4 (Method C) Alternative method for thepreparation of the compounds of Examples 2.01 or 3.01(a) (£)-2-Chloro-l-{3-{(lif,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyI)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl} hydrogen 2-butenedioate monochlorideTo a solution of the product from Synthetic Example 3, step e (2.5 g, 5.2 mmol) andimidazole (0.35 g, 5.2 mmol) in CH2C12 (35 mL) at -15°C was added a solution ofchloromaleic anhydride (0.69 g, 5.2 mmol) in CH2C12 (10 mL). After 10 min, themixture was diluted with CHC13 and washed with 2:1 brine / H20 containingmethanesulfonic acid (4 mg / mL). The organic layers were washed with brine, driedand evaporated to give the title compound as a yellow hygroscopic solid: MS m / z 578(M+, 100).(b) (Example 4.01) (Z)-2-Chloro-4-{3-[(lS,2i?)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl}-l-{3-{(l / ?,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquino!inio}propyl}-2-butenedioate dichlorideA solution of the product from step a (198 mg, 0.32 mmol), oxalyl chloride (281 |aL,3.2 mmol), and dimethyl formamide (DMF) (1 drop) in CH2C12 (4 mL) was heated atreflux for 2 h. The mixture was coevaporated with CH2C12 and dried in vacuo. Theresidue was dissolved in DCE (5 mL), the product mixture from Synthetic Example 1,step a (300 mg, 0.64 mmol) was added and the mixture was stirred at rt for 18 h. Thesolvent was evaporated and the crude material was purified as described in SyntheticExample 1, step c. Lyophilization provided the title product as a white solid (80 mg,23% yield): spectral data identical to that of the title product from Synthetic Example 2,step c.The following compound was prepared by a procedure similar to Synthetic Example 4:(Example 4.02): (Z)-2-Bromo-4-{3-[(15,2^)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio)propyl}-l-{3-{(l / f,2^S)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dibromideMS m / z 518 (M2+, 100).Synthetic Example 5 ( Method A)(a) 2,2-Difluorosuccinic anhydrideA mixture of 2,2-difluorosuccinic acid (1.15 g, 7.46 mmol), thionyl chloride (4 mL,20.6 mmol) and benzene (4 mL) was heated at reflux for 2.5 h. The mixture wasfiltered and the filtrate was concentrated to afford the title product as an oil thatcrystallized on standing (838 mg, 6.16 mmol, 83% yield).(b) 2,2-Difluoro-l-{3-{(li?,25' / f)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyI)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl} hydrogenbutanedioate monochlorideA solution of the 2.3:1 product mixture from Synthetic Example 1, step b (2.7 g, 5.60mmol) and the product from step a (838 mg, 6.16 mmol) in DCE (80 mL) was stirredovernight at rt. The solvent was evaporated to yield a 2.3:1 mixture of the (1R, 25)- and(1 / ?, 2 / ?)-title products, respectively as a yellow hygroscopic solid (3.5 g, 5.60 mmol,100% yield): MS m / z 582 (M+, 70).(c) (Example 5.01) 2,2-Difluoro-4-{3-[(lS,2tf)-6,7-dimethoxy-2-methyl-1 -(3,4,5-trimethoxyphenyl)-l ,2,3,4-tetrahydro-2-isoquinolinio] propyl} 1 - {3-{(l / ?,2iS)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-butanedioate dichlorideThe product mixture from step b (2.0 g, 3.24 mmol) was treated with oxalyl chlorideand then reacted with the product mixture from Synthetic Example 1, step a (1.73 g,3.10 mmol) as described in Synthetic Example 2, step c. The reaction mixture wasconcentrated and the resulting material was purified by MPLC as described in SyntheticExample 1, step c. Lyophilization provided the title product as a white solid (466 mg,27% yield): MS m / z 498 (M2+, 100).Synthetic Example 6 (Method B): Alternative method for thepreparation of the compound of Example 5.01(a) 2,2-Difluoro-l-{3-{(l / J,2S)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl} hydrogenbutanedioate monochlorideThe product from Synthetic Example 3, step e (3.0 g, 6.22 mmol) was treated in afashion similar to that described in Synthetic Example 5, step b. The title product wasobtained as a yellow hygroscopic solid (3.21 g, 83% yield): spectral data wereconsistent with the proposed structure.(b) (Example 6.01) 2,2-Dinuoro-4-{3-[(lS,2 / f;-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio] propyl}-1-{3-{(l / ?,25)-6,7-dimethoxy-2-methyI-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}butanedioate dichlorideThe product from step a (3.0 g, 4.85 mmol) was treated with oxalyl chloride and thenreacted with the product mixture from Synthetic Example 1, step a (2.44 g, 4.37 mmol)as described in Synthetic Example 2, step c. The reaction mixture was concentrated andthe resulting material was purified by MPLC as described in Synthetic Example 1, stepc. Lyophilization provided the title product as a white solid (1.3 g, 37% yield): thespectral data were identical to that of the title product from Synthetic Example 5, step c.The following compounds were prepared by procedures similar to SyntheticExample 6:(Example 6.02): 2,2-Difluoro-4-{3-[(15,25>-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl}-l-{3-{(l / ?,2.V)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}butanedioate dichlorideMS m / z 498 (M2+, 100).(Example 6.03): (2^5)-4-{3-[(15,2 / ?>6,7-Dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,354-tetrahydro-2-isoquinolinio]propyl}-l-{3-{(l / f,2S)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-fluorobutanedioate dichlorideMS m / z 489 (M2+, 55).(Example 6.04): (2 / ?5)-4-{3-[(lS,25>-6,7-Dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,23,4-tetrahydro-2-isoquinolinio]propyl}-l-{3-{(l / ?,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyI)methyI]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-fluorobutanedioate dichlorideMS m / z 489 (M2+, 30).Synthetic Example 7 Alternative method for the preparation ofthe compounds of Examples 5.01 and 6.01(a) (Example 7.01): 2,2-Difluoro-4-{3-[(15,2 / ?>-6,7-dimethoxy-2-methv 1-1-(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydro-2-isoquinolinio] propyl}-1-{3-{(l / f,25)-6,7-dimethoxy-2-methyl-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}butanedioate dichlorideNeat oxalyl chloride (25 mL, 0.28 mol) was added dropwise to a solution of the productfrom Synthetic Example 6, step a (7.0 g, 11.0 mmol) in DCE (150 mL). The solutionwas stirred at rt for 3.5 h. The solvent and excess oxalyl chloride were removed atreduced pressure and the remaining foam was reconstituted in DCE (35 mL). Asolution of the product from Synthetic Example 3, step c (4.7 g, 10.0 mmol) in DCE (35mL) was added and the reaction mixture was stirred overnight at rt. The solvent wasevaporated and the product was purified by MPLC as described in Synthetic Example1, step c. Lyophilization provided the title product as a white solid (5.63 g, 53% yield)with spectral data identical to that of the title product from Synthetic Example 5, step c.The following compound was prepared by procedures similar to SyntheticExample 7:(Example 7.02): 2,2-Difluoro-4-{3-[(15,2 / ?;-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,2,3,4-tetrahydro-2-isoquinolinio]propyl}-l-{3-{(l / ?,25)-2-methyl-6,7,8-trimethoxy-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}butanedioate dichlorideMS m / z 513 (M2+, 100).Synthetic Example 8(Example 8.01): (Z)-4-{3-[(15,2 / f)-6,7-Dimethoxy-2-methyl-l-(3,4,5-trimethoxy phenyl)-1,2,3,4-tetrahydro-2-isoquinolinio] propyl}-1-{3-{(l / ?,2.V)-6,7-dimethoxy-2-methyI-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-fluoro-2-butenedioate dichlorideSolid K2C03 (97 mg, 0.702 mmol) was added to a solution of the title product fromSynthetic Example 7 (750 mg, 0.702 mmol) in DMF (5 mL) and the mixture was stirredat rt for lh and then filtered. The filtrate was diluted with CHC13 (50 mL) and washedwith 1:1 brine / H20 (pH~l). The organic layer was dried and concentrated and theresidue was triturated with Et20 and purified as described in Synthetic Example 1, stepc. The title product was obtained as a white powder (404 mg, 0.385 mmol, 52% yield):MS m / z 488 (M2+, 80).The following compound was prepared by a procedure similar to SyntheticExample 8:(Example 8.02): (Z)-4-{3-[(15,2 / f)-6,7-Dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)-l,23,4-tetrahydro-2-isoquinolinio]propyI}-l-{3-{(l / f,25)-2-methyl-6,7,8-trimethoxy-l-[(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2-fluoro-2-butenedioate dichlorideAnal. Calcd for C54H71 N2015C12Fo5H20: C, 55.52; H, 6.99; N, 2.40; CI, 6.07. Found:C, 55.52; H, 6.96; N, 2.40; CI, 6.15.Biological ActivityCats were anesthetized with alpha-chloralose (80 mg / kg) and pentobarbital (10mg / kg) i.p. See J.J. Savarese Anesthesia and Analgesia, Vol. 52, No. 6, November-December, (1973). Square-wave stimuli were applied at supramaximal voltage to theperoneal nerve at 0.15 Hz and the evoked twitches of the tibialis anterior muscle wererecorded.Rhesus monkeys were anesthetized with ketamine (5 mg / Kg) and pentobarbitol(5 mg / Kg) given intramuscularly or intravenously. Anesthesia was maintained with amixture of halothane (0.25-0.75%), nitrous oxide (60%) and oxygen (40%). Thecommon peroneal nerve was stimulated supramaximally with square wave pulses of 0.2m sec duration at a rate of 0.15 Hz. Twitch contractions were recorded via the tendonof the extensor digitorum muscle.In all animals, the trachea was intubated and ventilation was controlled at 12-15ml / kg, 18-24 breaths per minute. Animals not receiving inhalation anesthetics wereventilated with room air. The left femoral vein and artery were cannulated for drugadministration and for recording or arterial pressure, respectively. Compounds ofFormula I listed in Table 1 were administered intravenously. The ED95, i.e., the doserequired to produce 95% block of the twitch response of compounds of Formula (I) isprovided in Table 1. Absence of data for particular parameters of particular examplenumbers indicates that data were not available.Table 1. Neuromuscular Blocking Activity in Rhesus Monkey
Claims
Claims 1. A compound of Formula (I) 5 wherein: X is halogen; h is from 1 to 2; Y is hydrogen or methoxy; I 2 Z and Z are methyl; I 2 10 W and W are carbon; and A is a pharmaceutically acceptable anion.
2. A compound of Formula (I) which includes: (Z)-2-Chloro-4- {3-[( 1S, 27?)-6,7-dimethoxy-2-methyl-1 -(3,4,5-trimethoxyphenyl)15 1,2,3,4-tetrahydro-2-isoquinolinio]propyl} -1 - {3- {(1R, 25)-6,7-dimethoxy-2-methyl-1 38 [(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2-isoquinoIinio}piOpyl}-2butenedioate dichloride, 2.2- Difluoro-4-{3-[(15',2 / ?)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)1.2.3.4- tetrahydro-2-isoquinolinio]propyl} 1-(3-(( 17?, 2S)-6,7-dimethoxy-2-methyl-l5 [(3,4,5-trimethoxypheny l)methy 1]-1,2,3,4-tetrahydro-2-isoquinolinio} propyl} butanedioate dichloride;, (Z)-4-{3-[(15,2R)-6,7-Dimethoxy-2-methyl-l -(3,4,5-trimethoxypheny 1)-1,2,3,4tetrahydro-2-isoquinolinio]propyl} -1-{3-{(17?,25)-6,7-dimethoxy-2-methyl-1 -[(3,4,5trimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-2-isoquinolinio}propyl}-2 -fluoro-210 butenedioate dichloride and 2.2- Difluoro-4-{3-[(15,2 / ?)-6,7-dimethoxy-2-methyl-l-(3,4,5-trimethoxyphenyl)1.2.3.4- tetrahydro-2-isoquinol iniojpropyl }-l-{3-{(17?, 2S)-2-methy 1-6,7,8-trimethoxy-1 [(3,4,5-trimethoxyphenyl)methyl]-l,2,3,4-tetrahydro-2isoquinolinio}propyl}butanedioate dichloride.
3. A pharmaceutical composition comprising a compound acccording to claim 1 or claim 2 in association with one or more pharmaceutically acceptable carriers.
4. The use of an effective neuromuscular paralyzing amount of a compound according to claim 1 or claim 2 in the manufacture of a medicament for inducing neuromuscular paralysis in a mammal.
5. A compound according to claim 1 or claim 2 for use in inducing neuromuscular blockade in mammals, including humans.
6. Use of a compound according to claim 1 or claim 2 for the manufacture of a medicament for inducing neuromuscular blockade.
7. A compound of Formula (II) A CH,O. r J: CH3O COT •v. · X 1 W (CH2)3 I o (CH2)n U OCH, (II) CH3O OCH, wherein: X is halogen; 10 T is hydroxyl or halide; Z is methyl; W is carbon; n is 0 or 1; h is 1 or 2; and 5 A is a pharmaceutically acceptable anion.
8. A process for the preparation of a compound of Formula (lb) ch3o wherein h is 1; and 5 X, Y, Z1, Z2, W1, W2, and A are as defined in claim 1 which comprises reacting a compound of Formula (Ia) CHjO wherein: h is 2; and 10 X, Y, Z1, Z2, W1, W2, and A are as defined in claim 1 with a base in a polar aprotic solvent.
9. A process for the preparation of a compound of Formula (1) comprising reacting a compound of Formula (II) as defined in claim 7 with a compound of Formula (ΙΠ) 5 wherein: Y is hydrogen or methoxy; Z is methyl; W is carbon; n is 0 or I; and10 A is a pharmaceutically acceptable anion in an organic solvent.
